Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | ZM008 |
| Trade Name | |
| Synonyms | ZM-008|ZM 008 |
| Drug Descriptions |
ZM008 is an anti-LLT1 monoclonal antibody that impairs the interaction between LLT1 and CD161, potentially leading to enhanced antitumor immune response and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2023;11; Cancer Res (2024) 84 (6_Supplement): 7535). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| ZM008 | ZM008 | 0 | 1 |